| Hint | Answer | % Correct | |
|---|---|---|---|
| Anti-hypertensives | Diuretic | Furosemide | 80%
|
| Anti-dysrhythmics | Gi coupled -> increased K-ATP | Adenosine | 40%
|
| Reperfusion Injury | Ischaemia creates ROS and | AMP | 40%
|
| PCSK9 inhibitorPrevents recyling of LDL Familial Hypercholesterolaemia is LDLR mutation | Evolocumab | 40%
| |
| Angina | Collateral VasodilatorLiver converts to mononitrate (induces NO production) | Glyceryl trinitrate | 40%
|
| PCSK9 inhibitor (siRNA) | Inclisiran | 40%
| |
| Funny current blocker (via HCN) | Ivabradine | 40%
| |
| Calcium Blocker | Verapamil | 40%
| |
| calcium blocker | verapamil | 40%
| |
| False Transmitter, a2 agonist | aMethylDOPA | 20%
| |
| Atherosclerosis | HMG-CoA Reductase inhibitorimpairs cholesterol synth ↑LDL uptake in liver | Arvostatin | 20%
|
| beta blocker | Atenolol | 20%
| |
| beta antagonist | atenolol | 20%
| |
| Inhibits citrate production (needed +CoA to make cholesteol) | Bempedoic Acid | 20%
| |
| Fibrate - ↑lipoprotein lipase to release TAGs from VLDL to be absorbed by muscles | Bezafibrate | 20%
| |
| Cleaved twice to release a ___ type TF | bHLH | 20%
| |
| SCAP are | chaperones | 20%
| |
| Bile reabsorption inhibitor | Cholestyramine | 20%
| |
| a2 antagonist (Gi --> ↓NT Release) | Clonidine | 20%
| |
| Non-collateral vasodilator (diverts blood way from ischaemic region) | Dipyridamole | 20%
| |
| Inhibits intestinal cholesterol uptake (enterogepatic recirculation) | Ezetimibe | 20%
| |
| reduces hypertriglyceridaemia cia arachidonic acid replacement | fish oil | 20%
| |
| Sulphonylurea | Glibenclamide | 20%
| |
| Leaves ER to | Golgi | 20%
| |
| SREBP/SCAP Pathway | on what gene | INSIG | 20%
|
| which opens | K-ATP | 20%
| |
| Potassium Channel OpenerOpens K-ATP Hirsutism Severe Refractory Hypertension | Minoxidil | 20%
| |
| Imidazoline Receptor AgonistI1R is central GPCR -> ↑DAG + ArachAcid | Moxonidine | 20%
| |
| Which opens ____ in the mitochondria (close in ischaemia to prevent damage) | MPTP | 20%
| |
| Treat with ATP preservation drug or by opening K-ATP channels | Nicorandil | 20%
| |
| Stops liver TAG production and VLDL secretion + anticoagulative | nicotinic acid | 20%
| |
| Reverse Cholesterol Transport Pathway | PPAR AgonistPPAR -> ↑Liver X Receptors -> ↑ABCA1 ->↑HDL | Pioglitazone | 20%
|
| AMP leads to activation of | PKC | 20%
| |
| ACE Inhibitor | Ramipril | 20%
| |
| Late Na Current blocker, ↓NCX -> ↓Ca overload -> relaxation not impaired | Ranolazine | 20%
| |
| also treat with bypass or | stents | 20%
|